NCT06889506

Brief Summary

assessment of the level of interleukin 4 (IL-4) in the lesional skin and serum of PLC patients and compare its level with healthy controls.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2025

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 16, 2025

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 21, 2025

Completed
11 days until next milestone

Study Start

First participant enrolled

April 1, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

March 21, 2025

Status Verified

January 1, 2025

Enrollment Period

3 months

First QC Date

March 16, 2025

Last Update Submit

March 16, 2025

Conditions

Pityriasis Lichenoides

Outcome Measures

Primary Outcomes (1)

  • Assessment of tissue and serum levels of interleukin 4 (IL -4) in pityriasis lichenoides chronica (PLC) patients and normal controls.

    measurement of tisssue and serum levels of interleukin 4 (IL -4) in pityriasis lichenoides chronica (PLC) patients and comparing them with normal controls to control and verify the hypothesisof involvement of IL-4 in the pathogenesis of PLC

    6 months

Study Arms (2)

PLC patients

ACTIVE COMPARATOR

one skin biopsy (lesional) and serum sample will be taken from every patient

Procedure: skin biopsy and serum sample

healthy controls

EXPERIMENTAL

a skin biopsy and serum sample will be taken from each control sample

Procedure: skin biopsy and serum sample

Interventions

skin biopsy and serum samplePROCEDURE

skin biopsy from lesional skin and serum sample will be taken from each patient . also a skin biopsy and serum sample will be taken from each healthy control

PLC patientshealthy controls

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with pityriasis lichenoides Chronica (PLC): either with the classical presentation papular or hypo-pigmented macules and patches that proved histopathologically to be PLC.
  • Both genders
  • Age group ≥ 8 years

You may not qualify if:

  • Patients with other skin diseases
  • Patient received treatment for PLC within period less than three months
  • Pregnant patients
  • Lactating patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Pityriasis Lichenoides

Condition Hierarchy (Ancestors)

Lichenoid EruptionsSkin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue DiseasesParapsoriasisPityriasis

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

March 16, 2025

First Posted

March 21, 2025

Study Start

April 1, 2025

Primary Completion

July 1, 2025

Study Completion

July 1, 2025

Last Updated

March 21, 2025

Record last verified: 2025-01